First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received prior treatments in the advanced setting. It will also look at whether the effectiveness of the drug differs between TNBC adults with homologous recombination deficiency (HRD) subtypes and those with non-HRD subtypes. The main questions this study aims to answer are: * Will patients with advanced TNBC who haven't received prior treatment in the advanced setting respo

Trial Details

NCT ID
NCT07299409
Phase
PHASE2
Sponsor
Nathalie Levasseur
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Sacituzumab Govitecan (SG)
Locations (sample)
  • Vancouver, British Columbia, Canada|49.24966,-123.11934

Key Eligibility Criteria

  • Participants must meet all the following criteria to be eligible for participation in this study:
  • Willing and able to provide informed consent.
  • Age \>18 years old at the time of informed consent and has signed informed consent before any trial related activities are conducted according to l…
  • For participants of child-bearing potential (menstruation within \<2 years): negative serum pregnancy test within 14-days prior to enrollment and m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →